KMKelli M. Money

Kelli M. Money

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kelli M. Money has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diagnostic Accuracy of Oligoclonal Bands for CNS Autoimmune Disorders in Acutely Ill Adults

    by Jarrett Leech, Brian M. Sauer, Amiran Baduashvili, John R. Corboy, Thomas Edward Ragole, Stefan Sillau, Russell J. Van Coevering, Dana Coutts, Ivan Trang, Kelli M. Money, et al.

    The presence of oligoclonal bands (OCBs) indicates an augmented immune response within the CNS and is integral to the diagnosis of multiple sclerosis (MS). Expert consensus panels recommend OCB testing for conditions other than MS, despite limited data to suggest diagnostic value. Our objectives were to evaluate the spectrum of disease etiologies associated with OCBs and determine the accuracy of OCBs in identifying autoimmune disorders affecting the CNS. This is a retrospective, observational, single health system study that captured all patients in acute care settings who underwent OCB testing from January 1, 2018, through December 31, 2020. Patient diagnoses and diagnostic categories were adjudicated by clinicians. Test accuracy characteristics to detect CNS autoimmune disorders were computed by comparing 2 or more OCBs as a positive index test against target disease etiologies as reference standards. OCB testing was performed across all etiologies in 926 patients; 78 patients had MS, and 148 had CNS autoimmune disorders not related to MS. Oligoclonal bands exhibited high sensitivity for MS but low sensitivity and low predictive power for other CNS autoimmune disorders. In contrast to their diagnostic accuracy in MS, OCBs exhibited limited discriminatory power in the detection of other autoimmune disorders affecting the CNS. Beyond suspected MS, OCBs should not be relied on as an accurate diagnostic tool because a positive result can manifest in an array of neurologic diseases and a negative result does not exclude an autoimmune etiology.


  • West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies

    by Rumyar V. Ardakani, Paul Daniel Crane, Daniel M. Pastula, Lakshmi Chauhan, Elizabeth Matthews, Kelli M. Money, Anna Shah, Amanda L. Piquet, Robert H. Gross, Aaron M. Carlson, et al.

    The literature on severe West Nile virus (WNV) neuroinvasive disease (WNND) in patients treated with anti-CD20 therapies is limited. We systematically characterize cases of WNND in the tertiary academic UCHealth system. A retrospective cohort (January 2016 to January 2024) of patients with a validated diagnosis of WNND and anti-CD20 medication use was identified with electronic medical record query followed by individual chart review. We identified 25 patients; multiple sclerosis was the most common indication for anti-CD20 therapy in 13 patients (52%). Twenty-one patients (84%) presented with meningoencephalitis. CSF WNV IgM was positive in 5 of 21 patients (24%) who were tested while 13 of 14 tested patients (93%) had positive reverse-transcription PCR (RT-PCR) findings in the CSF. MRI demonstrated anomalies associated with WNND in 12 of 23 patients (52%) with available imaging. Intensive care unit admission was required in 8 patients (32%), and 12 patients (48%) were treated with intravenous immunoglobulin. Worsening of ≥1 point from pre-WNV baseline modified Rankin Scale (mRS) score to the 90-day postdischarge mRS score was seen in 18 patients (75%). Two patients (8%) died by 90 days. WNND leads to disability accrual in patients on B cell-depleting anti-CD20 therapies. Utilization of RT-PCR is important in optimizing diagnosis in this patient population because of limited sensitivity of the WNV-IgM testing commonly used in the general population.


  • Evaluation of Brain Abscess Prognostic Factors and Role of Surgical Intervention Within a Single Health System

    by Jamie E. Cronin, Timothy H. Ung, Amanda L. Piquet, Kelli M. Money

    Purpose: Evaluate patient, clinical, and treatment variables impacting mortality in patients with brain abscesses. Background: Brain abscesses are intraparenchymal infectious foci with significant morbidity and mortality. Management includes antimicrobial therapy +/− surgical intervention, and is dependent on suspected pathogen/source, patient factors, and clinician judgement. Treatment type and duration vary substantially and are often guided by imaging, inflammatory markers, and symptoms. Methods: 186 patients with brain abscesses admitted at a single health system between 2010 and 2022 were analyzed. Patient demographics, clinical course, diagnostic studies, and abscess treatment were assessed for impact on mortality during admission via univariate and stepwise multivariate nominal logistic regression. Secondary outcomes of surgical drainage were evaluated with univariate and multivariate nominal logistic regression, and survival over time of those who received surgical drainage vs those who did not was evaluated with Kaplan-Meier survival analysis. Results: 10.7% of patients died during initial admission. Intravenous drug use, deep-seated abscess location, and surgical complication were independently predictive of death during admission. Patients without surgical intervention demonstrated increased likelihood of mortality over time but not during admission. Independent predictors of surgical intervention include lack of ventriculitis, larger abscess diameter, non-hematogenous or -pulmonary source, and mass effect. Conclusions: These findings suggest surgical intervention is generally avoided when infection is systemic, severe, or with intraventricular abscess rupture. Patients with overt symptoms of brain infection were more likely to receive prompt surgical drainage. In our patient population, surgical drainage in addition to antimicrobial therapy did not independently impact inpatient mortality although did impact overall survival.


  • Open Access

    The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population

    by Aaron M. Carlson, Carlos E.V. Sollero, Andrew B. Wolf, Stefan Sillau, Barrie L. Schmitt, Kelli M. Money, Kavita V. Nair, Amanda L. Piquet, Jeffrey L. Bennett

    Objective: To define the epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder (NMOSD) in a large US health system.Methods: We completed a retrospective observational study of adult patients in the University of Colorado Health System from 1 January 2011 to 31 December 2020, using Health Data Compass (HDC), a data warehouse that combines electronic health information with claims and public health data in Colorado. We screened HDC for patients with either (1) an abnormal aquaporin‐4 IgG test or (2) any G36 ICD‐10 code. We extracted key clinical elements by chart review and confirmed diagnosis by the 2015 International Panel for NMO Diagnosis criteria. Annual incidence and prevalence rates were calculated.Results: Our population consisted of 2,475,591 individuals contributing 11,103,522.72 person‐years of observation. In total, 115 seropositive NMOSD patients were identified. The average yearly incidence was 0.22 per 100,000 person‐years. Age and sex‐adjusted prevalence (per 100,000) was 4.33, and highest among those identifying as Asian or Pacific Islander (17.72), and Black (14.74), as separately by Hispanic ethnicity (8.02). Prevalence was higher in women (6.20:1 female:male ratio). Transverse myelitis (45%) and optic neuritis (43%) were the most common presenting clinical syndromes. In total, 6% of initial presentations were characterized by short‐segment transverse myelitis without other features.Interpretation: Seropositive NMOSD incidence is higher in our cohort than many contemporary studies. Women and those identifying as Asian or Pacific Islander, Black, and Hispanic shoulder the highest burden of disease. Clinical onset with short‐segment myelitis underscores the need for serum aquaporin‐4 IgG testing in acute myelitis presentations.


  • Open Access

    CADASIL progression after neurologic infectious insults: Case report of a new pathogenic NOTCH3 mutation

    by Kelli M. Money, Jamie Cronin, Amy Guimaraes-Young, Aaron Carlson, Mark A. Lovell, Elizabeth Matthews, Karen D. Orjuela, Daniel M. Pastula, Eric P. Wartchow, Amanda L. Piquet


  • Reply to “MOG‐IgG‐Associated Bilateral Optic Neuritis in Temporal Relation to Monkeypox Vaccination”

    by Kelli M. Money, Takashi Kitani, Daniel M. Pastula

  • Open Access

    Monkeypox‐Associated Central Nervous System Disease: A Case Series and Review

    by Kelli M. Money, T. Allen Barnett, Samuel Rapaka, Rebecca Osborn, Takashi Kitani, Daniel Fuguet, Faria Amjad, Jeffrey R. Clark, Debanjana Chakravarty, Matthew J. Copeland, et al.

    Objective: Monkeypox virus (MPXV) disease has been declared a public health emergency by the World Health Organization, creating an urgent need for neurologists to be able to recognize, diagnosis, and treat MPXV‐associated neurologic disease.Methods: Three cases of MPXV‐associated central nervous system (CNS) disease occurring during the 2022 outbreak, and their associated imaging findings are presented, with 2 cases previously published in a limited capacity in a public health bulletin.Results: Three previously healthy immunocompetent gay men in their 30s developed a febrile illness followed by progressive neurologic symptoms with presence of a vesiculopustular rash. MPXV nucleic acid was detected by polymerase chain reaction (PCR) from skin lesions of 2 patients, with the third patient having indeterminate testing but an epidemiologic link to a confirmed MPXV disease case. Cerebrospinal fluid demonstrated a lymphocytic pleocytosis, elevated protein, and negative MPXV‐specific PCR. In 2 patients, magnetic resonance imaging of the brain and spine demonstrated partially enhancing, longitudinally extensive central spinal cord lesions with multifocal subcortical, basal ganglia, thalamic, cerebellar, and/or brainstem lesions. The third patient had thalamic and basal ganglia lesions. All patients received 14 days of tecovirimat, and 2 patients also received multiple forms of immunotherapy, including intravenous immunoglobulin, pulsed high‐dose steroids, plasmapheresis, and/or rituximab. Good neurologic recovery was observed in all cases.Interpretation: MPXV can be associated with CNS disease. It is unclear whether this is from a parainfectious immune‐mediated injury or direct CNS viral invasion. ANN NEUROL 2023;93:893–905